• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma.在接受达雷妥尤单抗作为其多发性骨髓瘤首次诱导治疗方案一部分的患者中，中性粒细胞植入延迟。
Am J Hematol. 2020 Jan;95(1):E8-E10. doi: 10.1002/ajh.25654. Epub 2019 Oct 21.
2
Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation.新型诱导疗法联合自体造血干细胞移植可降低多发性骨髓瘤患者移植后嵌合综合征发生率的创新策略。
Bone Marrow Transplant. 2018 Dec;53(12):1541-1547. doi: 10.1038/s41409-018-0189-2. Epub 2018 Apr 29.
3
Granulocyte colony-stimulating factor utilization postautologous hematopoietic stem cell transplant in multiple myeloma patients: Does one size fit all?多发性骨髓瘤患者自体造血干细胞移植后粒细胞集落刺激因子的应用：一种方案适用于所有人吗？
J Oncol Pharm Pract. 2019 Jul;25(5):1135-1141. doi: 10.1177/1078155218781888. Epub 2018 Jun 11.
4
Two novel assays demonstrate persistent daratumumab exposure in a pediatric patient with delayed engraftment following allogeneic hematopoietic stem cell transplantation.
Cytotherapy. 2024 May;26(5):466-471. doi: 10.1016/j.jcyt.2024.01.005. Epub 2024 Feb 29.
5
Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma.沙利度胺对多发性骨髓瘤患者干细胞采集及植入的影响。
Bone Marrow Transplant. 2003 Sep;32(6):587-92. doi: 10.1038/sj.bmt.1704173.
6
High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.大剂量美法仑联合噻替派作为“初治”多发性骨髓瘤患者第二次自体干细胞移植前的预处理方案：一项II期研究。
Biol Blood Marrow Transplant. 2015 Nov;21(11):1932-8. doi: 10.1016/j.bbmt.2015.06.011. Epub 2015 Jun 19.
7
[The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].硼替佐米为基础的诱导方案在多发性骨髓瘤患者自体造血干细胞移植前的疗效与安全性
Zhonghua Nei Ke Za Zhi. 2012 Apr;51(4):279-83.
8
Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.适合自体干细胞移植的多发性骨髓瘤患者中预处理方案毒性的比较：大剂量美法仑与大剂量美法仑联合硼替佐米
J Oncol Pharm Pract. 2018 Jun;24(4):281-289. doi: 10.1177/1078155217697486. Epub 2017 Mar 21.
9
Toxicity of autologous hematopoietic cell transplantation in patients with multiple myeloma - comparison between two different induction regimens.自体造血细胞移植治疗多发性骨髓瘤的毒性 - 两种不同诱导方案的比较。
Clin Transplant. 2012 Sep-Oct;26(5):E549-54. doi: 10.1111/ctr.12018.
10
Hematopoietic engraftment of dimethyl sulfoxide-depleted autologous peripheral blood progenitor cells.二甲基亚砜去除后的自体外周血祖细胞的造血植入
Transfusion. 2009 Feb;49(2):354-61. doi: 10.1111/j.1537-2995.2008.01949.x. Epub 2008 Oct 28.

引用本文的文献

1
First-Line Use of Daratumumab in Patients with Multiple Myeloma Shows Delayed Neutrophil and Platelet Engraftment after Autologous Stem Cell Transplantation: Results from a Real-Life Single-Center Study.达雷妥尤单抗在多发性骨髓瘤患者中的一线应用显示自体干细胞移植后中性粒细胞和血小板植入延迟：一项真实世界单中心研究的结果
Cancers (Basel). 2024 Sep 27;16(19):3307. doi: 10.3390/cancers16193307.
2
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients-A Systematic Review.抗CD38单克隆抗体疗法对多发性骨髓瘤患者CD34+造血干细胞动员、采集及植入的影响——一项系统评价
Pharmaceuticals (Basel). 2024 Jul 15;17(7):944. doi: 10.3390/ph17070944.
3
Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery.达雷妥尤单抗用于骨髓瘤诱导治疗时与干细胞动员受损及移植后血液学恢复延长相关。
Cancers (Basel). 2024 May 13;16(10):1854. doi: 10.3390/cancers16101854.
4
Effect of prior lenalidomide or daratumumab exposure on hematopoietic stem cell collection and reconstitution in multiple myeloma.来那度胺或达雷妥尤单抗预先暴露对多发性骨髓瘤患者造血干细胞采集和重建的影响。
Ann Hematol. 2024 Oct;103(10):3839-3853. doi: 10.1007/s00277-024-05683-2. Epub 2024 Mar 6.
5
A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation.一项关于德国范围内多发性骨髓瘤动员不佳患者在自体干细胞移植前造血干细胞动员与采集的系统性研究。
Transfus Med Hemother. 2023 Oct 16;50(6):475-490. doi: 10.1159/000531935. eCollection 2023 Dec.
6
The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma.单克隆抗体在双特异性抗体和嵌合抗原受体T细胞疗法时代对多发性骨髓瘤的作用
Cancers (Basel). 2021 Sep 29;13(19):4909. doi: 10.3390/cancers13194909.
7
Peri-transplant Stem Cell Kinetics After Daratumumab-Based Induction in Patients with Multiple Myeloma: Response to Mishra et al.达雷妥尤单抗诱导治疗的多发性骨髓瘤患者移植后干细胞动力学：对米什拉等人研究的回应
Indian J Hematol Blood Transfus. 2020 Oct;36(4):763-765. doi: 10.1007/s12288-020-01273-0. Epub 2020 Mar 17.
8
EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma.EMA 审查达雷妥尤单抗（Darzalex）治疗新诊断为多发性骨髓瘤的成年患者。
Oncologist. 2020 Dec;25(12):1067-1074. doi: 10.1002/onco.13554. Epub 2020 Oct 16.
9
Daratumumab in untreated newly diagnosed multiple myeloma.达雷妥尤单抗用于未经治疗的新诊断多发性骨髓瘤
Ther Adv Hematol. 2019 Dec 23;10:2040620719894871. doi: 10.1177/2040620719894871. eCollection 2019.

本文引用的文献

1
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗用于新诊断多发性骨髓瘤患者自体造血干细胞移植前后（CASSIOPEIA）：一项随机、开放标签、3 期研究。
Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3.
2
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.达雷妥尤单抗联合治疗多发性骨髓瘤患者的药代动力学和暴露-反应分析。
Adv Ther. 2018 Nov;35(11):1859-1872. doi: 10.1007/s12325-018-0815-9. Epub 2018 Oct 29.
3
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.多发性骨髓瘤修订国际分期系统：国际骨髓瘤工作组报告
J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3.
4
International staging system for multiple myeloma.多发性骨髓瘤国际分期系统
J Clin Oncol. 2005 May 20;23(15):3412-20. doi: 10.1200/JCO.2005.04.242. Epub 2005 Apr 4.
5
Human CD38: a glycoprotein in search of a function.人类CD38：一种寻找功能的糖蛋白。
Immunol Today. 1994 Mar;15(3):95-7. doi: 10.1016/0167-5699(94)90148-1.
6
Characterization of a murine monoclonal antibody specific for human early lymphohemopoietic cells.
Hum Immunol. 1984 Jan;9(1):9-20. doi: 10.1016/0198-8859(84)90003-x.

Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma.

作者信息

Al Saleh Abdullah S, Sidiqi M Hasib, Gertz Morie A, Muchtar Eli, Lacy Martha Q, Warsame Rahma M, Gonsalves Wilson I, Kourelis Taxiarchis V, Hogan William J, Hayman Suzanne R, Kapoor Prashant, Buadi Francis K, Dispenzieri Angela, Dingli David, Kumar Shaji K

机构信息

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.

King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.

出版信息

Am J Hematol. 2020 Jan;95(1):E8-E10. doi: 10.1002/ajh.25654. Epub 2019 Oct 21.

DOI:10.1002/ajh.25654
PMID:31591735
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7388699/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7937/7388699/afdee7fd42b1/nihms-1607584-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7937/7388699/afdee7fd42b1/nihms-1607584-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7937/7388699/afdee7fd42b1/nihms-1607584-f0001.jpg